Anika Therapeutics Affirms FY2024 Sales Guidance Of $168M-$173M Vs, $170.84M Estimate

Benzinga · Aug 9 05:04

Fiscal 2024 Guidance
Anika continues to expect that revenue for fiscal 2024 will be in the range of $168 to $173 million, representing growth of 1% to 4% compared to 2023.

Revenue ranges by product family are:

OA Pain Management of $102 to $104 million, up 0% to 2%
Joint Preservation and Restoration of $58 to $60.5 million, up 6% to 10%
Non-Orthopedic of $8 to $8.5 million, down 14% to 19%

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.

Anika Therapeutics Affirms FY2024 Sales Guidance Of $168M-$173M Vs, $170.84M Estimate

Risk Disclaimer